Scottish Medicines Consortium Issues Positive Advice on Evoltra(R)

Bioenvision Limited (NasdaqGM: BIVN) today announced the Scottish
Medicines Consortium (SMC) released positive advice on the use of
Evoltra(R) (clofarabine) within NHS Scotland.

The release of this positive advice ensures funding is now
available for Evoltra, which is a new treatment option for children
with acute lymphoblastic leukaemia (ALL) who have relapsed or are
refractory to the standard treatment options.

"The prognosis for children with relapsed/refractory ALL is very
poor, and the availability of Evoltra is great news for patients and
their families," said Hugh Griffith, Chief Operating Officer of
Edinburgh based Bioenvision. "We believe that Evoltra offers genuine
hope and a real chance for prolonged survival in children who have
exhausted all standard therapies and are very pleased that the SMC has
issued this positive advice and that the funding for Evoltra will now
be in place."

"Treatment for children with leukaemia in Scotland has improved
dramatically over the last three decades. However, for children with
resistant disease the prognosis remains poor and any new drug or
treatment that offers hope for this group of patients and their
families is welcomed," commented Dr Brenda Gibson, Consultant
Haematologist, Royal Hospital for Sick Children, Yorkhill, Glasgow,
Scotland, UK.

About Evoltra(R) (clofarabine)

The European Marketing Authorization for Evoltra(R) (clofarabine)
is for "the treatment of acute lymphoblastic leukaemia (ALL) in
paediatric patients who have relapsed or are refractory to at least
two prior regimens and where there is no other treatment option
anticipated to result in a durable response. Safety and efficacy have
been assessed in studies of patients